TORONTO (Reuters) – Canada’s government health agency said on Tuesday it is working with the U.S. Food and Drug Administration to address a shortage of Mylan N.V.’s EpiPen emergency allergy antidote that has hit several countries outside of the United States, where it is manufactured.